Accurate characterization of tissue biodistribution (BD) is essential for the development of new drug and imaging agents. Recently, a novel method to quantify tissue-specific BD of fluorescent imaging agent has been developed and characterized. A subsequent tissue BD study, using this method, was performed in mice with subcutaneous tumor xenograft of head and neck squamous cell carcinoma (NHSCC). Here we utilized the same method to characterize tissue BD of two imaging agents, ABY-029 and IRDye 680LT in mouse orthotopic HNSCC tumor model. Tissue-specific fluorescence intensities were measured 5h after imaging agent administration. The two imaging agents shared similar trends of relative fluorescence intensities across ten types of tissue. Highest tissue-specific fluorescence values were observed in kidney and liver for both imaging agents while brain and muscle showed the lowest distribution for both agents.
Paired-Agent Imaging (PAI) is a quantitative fluorescence imaging technique that estimates the drug target concentration. It involves the co-administration of a targeted and an untargeted imaging probe to correct for nonspecific uptake and to quantify the available receptor concentration, known as the binding potential. PAI has been demonstrated in a pre-clinical setting using a 1:1 molar concentration of the targeted, ABY-029, and untargeted, IRDYE 680LT, imaging agent. However, the effects of different molar concentrations of imaging agents on the binding potential have not been studies thus far. In this study, we examined this relationship in tissue-mimicking liquid phantoms with varying molar concentration ratios. The phantom fluorescence was measured using the Pearl Imaging system and then the binding potential was quantified using MATLAB. We determined that the binding potential remains stable across concentration but increases for dye ratios where the targeted dye is higher.
SignificanceFluorescence guidance is used clinically by surgeons to visualize anatomical and/or physiological phenomena in the surgical field that are difficult or impossible to detect by the naked eye. Such phenomena include tissue perfusion or molecular phenotypic information about the disease being resected. Conventional fluorescence-guided surgery relies on long, microsecond scale laser pulses to excite fluorescent probes. However, this technique only provides two-dimensional information; crucial depth information, such as the location of malignancy below the tissue surface, is not provided.AimWe developed a depth sensing imaging technique using light detection and ranging (LiDAR) time-of-flight (TOF) technology to sense the depth of target tissue while overcoming the influence of tissue optical properties and fluorescent probe concentration.ApproachThe technology is based on a large-format (512×512 pixel), binary, gated, single-photon avalanche diode (SPAD) sensor with an 18 ps time-gate step, synchronized with a picosecond pulsed laser. The fast response of the sensor was developed and tested for its ability to quantify fluorescent inclusions at depth and optical properties in tissue-like phantoms through analytical model fitting of the fast temporal remission data.ResultsAfter calibration and algorithmic extraction of the data, the SPAD LiDAR technique allowed for sub-mm resolution depth sensing of fluorescent inclusions embedded in tissue-like phantoms, up to a maximum of 5 mm in depth. The approach provides robust depth sensing even in the presence of variable tissue optical properties and separates the effects of fluorescence depth from absorption and scattering variations.ConclusionsLiDAR TOF fluorescence imaging using an SPAD camera provides both fluorescence intensity images and the temporal profile of fluorescence, which can be used to determine the depth at which the signal is emitted over a wide field of view. The proposed tool enables fluorescence imaging at a higher depth in tissue and with higher spatial precision than standard, steady-state fluorescence imaging tools, such as intensity-based near-infrared fluorescence imaging, optical coherence tomography, Raman spectroscopy, or confocal microscopy. Integration of this technique into a standard surgical tool could enable rapid, more accurate estimation of resection boundaries, thereby improving the surgeon’s efficacy and efficiency, and ultimately improving patient outcomes.
Receptor occupancy (RO) correlates the dose of drug administered to the percentage of receptors occupied by the drug compound, which helps decide dosing of drug candidates entering clinical trials, and tailor drug dosage for individualized therapies. However, in vivo measurement of RO in solid tumor is hindered by both tissue properties and technical limitations. Here we present the progress of developing a near-infrared, paired-agent imaging (PAI) approach for real-time measurement of anti-tumor drug RO in vivo. In this study, xenograft murine model with orthotopic tumor implant was imaged using a pair of imaging agent: ABY-029, an affibody-dye conjugate, targeting epidermal growth factor receptor (EGFR), together with IRDye 680LT, a pharmacokinetically similar probe devoid of EGFR specificity. Concentration of tumor EGFR free of drug binding was quantified by binding potential (BP), a parameter calculated from fluorescence signals of the agent pair. We demonstrated that BP was decreased by subsequent administration of drug homolog, indicating drug-EGFR engagement in the tumor. The results demonstrated the ability of PAI to reflect displacement of EGFR-bound ABY-029 by anti-EGFR drug molecules, and the potential to be applied for in vivo RO measurement.
Access to the requested content is limited to institutions that have purchased or subscribe to SPIE eBooks.
You are receiving this notice because your organization may not have SPIE eBooks access.*
*Shibboleth/Open Athens users─please
sign in
to access your institution's subscriptions.
To obtain this item, you may purchase the complete book in print or electronic format on
SPIE.org.
INSTITUTIONAL Select your institution to access the SPIE Digital Library.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.